| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.1 | 0.05 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.093 | 0.06 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | -0.086 | 0.09 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.082 | 0.09 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.075 | 0.1 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.069 | 0.2 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.057 | 0.2 |